Overview
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
The book contains black-and-white illustrations.
Editorials
From The Critics
Reviewer: Satya Murthy, PhD(Evanston Hospital)Description: This book is intended to guide cancer researchers through the processes and procedures for developing new anticancer drugs and for obtaining final approval..
Purpose: The title clearly states the purpose of the book, and the purpose is fairly well met. The objectives of the book are worthwhile.
Audience: This book is written for cancer researchers, particularly for those involved in drug development areas. It helps readers to gain insight into drug development.
Features: The editor of this book is a well-known investigator in experimental therapeutics who has made significant contributions relating to cisplatin effects and acquired drug resistance and has attracted several outstanding researchers to contribute to the book.
Assessment: This book contains some very valuable chapters, notable among them are those authored by Hanauske et al. and Corbott et al. Some chapters, however, lack an in-depth treatment of the subject matter and also fail to focus on the intended topic. Chapters dealing with topics such as local recurrence and distant metastasis, cytokines and hormones, antibody and antisense probes are prominently absent. The book could have used rigorous care in editing to avoid spelling and typographical errors. These flaws temper the enthusiasm to strongly recommend this book. Nevertheless, it deserves a place as a reference book in the libraries serving students of oncology.
Satya Murthy
This book is intended to guide cancer researchers through the processes and procedures for developing new anticancer drugs and for obtaining final approval.. The title clearly states the purpose of the book, and the purpose is fairly well met. The objectives of the book are worthwhile. This book is written for cancer researchers, particularly for those involved in drug development areas. It helps readers to gain insight into drug development. The editor of this book is a well-known investigator in experimental therapeutics who has made significant contributions relating to cisplatin effects and acquired drug resistance and has attracted several outstanding researchers to contribute to the book. This book contains some very valuable chapters, notable among them are those authored by Hanauske et al. and Corbott et al. Some chapters, however, lack an in-depth treatment of the subject matter and also fail to focus on the intended topic. Chapters dealing with topics such as local recurrence and distant metastasis, cytokines and hormones, antibody and antisense probes are prominently absent. The book could have used rigorous care in editing to avoid spelling and typographical errors. These flaws temper the enthusiasm to strongly recommend this book. Nevertheless, it deserves a place as a reference book in the libraries serving students of oncology.Booknews
Researchers from pharmaceutical companies, government laboratories, and academia review and describe the process of cancer drug discovery and approval. They discuss using preclinical "in vivo" and "in vitro" methods to identify molecules of interest, detail the targets and criteria for success in each type of testing, define the value of information obtained from various tests, and show how to work with the NCI, EORTC, and FDA for approval. For cancer researchers and physicians in drug development, and regulatory officials in pharmaceutical firms. Annotation c. by Book News, Inc., Portland, Or.2 Stars from Doody